Literature DB >> 26468184

New Perspectives for the Rescue of Cognitive Disability in Down Syndrome.

Renata Bartesaghi1, Tarik F Haydar2, Jean Maurice Delabar3, Mara Dierssen4, Carmen Martínez-Cué5, Diana W Bianchi6.   

Abstract

Down syndrome (DS) is a relatively common genetic condition caused by the triplication of human chromosome 21. No therapies currently exist for the rescue of neurocognitive impairment in DS. This review presents exciting findings showing that it is possible to restore brain development and cognitive performance in mouse models of DS with therapies that can also apply to humans. This knowledge provides a potential breakthrough for the prevention of intellectual disability in DS.
Copyright © 2015 the authors 0270-6474/15/3513843-10$15.00/0.

Entities:  

Keywords:  Down syndrome; brain abnormalities; intellectual disability; mouse models; preventive therapies

Mesh：

Year:  2015        PMID： 26468184      PMCID： PMC6608177          DOI： 10.1523/JNEUROSCI.2775-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN： 0270-6474            Impact factor:   6.167


  9 in total

1.  Treating trisomies: Prenatal Down's syndrome therapies explored in mice.

Authors:  Bridget M Kuehn
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

Review 2.  Mouse models of Down syndrome: gene content and consequences.

Authors:  Meenal Gupta; A Ranjitha Dhanasekaran; Katheleen J Gardiner
Journal:  Mamm Genome       Date:  2016-08-18       Impact factor: 2.957

3.  Modeling Fragile X syndrome in neurogenesis: An unexpected phenotype and a novel tool for future therapies.

Authors:  Barbara Bardoni; Maria Capovilla; Enzo Lalli
Journal:  Neurogenesis (Austin)       Date:  2017-01-31

4.  The Arizona Cognitive Test Battery for Down Syndrome: Test-Retest Reliability and Practice Effects.

Authors:  Jamie O Edgin; Payal Anand; Tracie Rosser; Elizabeth I Pierpont; Carlos Figueroa; Debra Hamilton; Lillie Huddleston; Gina Mason; Goffredina Spanò; Lisa Toole; Mina Nguyen-Driver; George Capone; Leonard Abbeduto; Cheryl Maslen; Roger H Reeves; Stephanie Sherman
Journal:  Am J Intellect Dev Disabil       Date:  2017-05

5.  Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome.

Authors:  Jan M Schulz; Frederic Knoflach; Maria-Clemencia Hernandez; Josef Bischofberger
Journal:  J Neurosci       Date:  2019-04-18       Impact factor: 6.167

6.  Environment as therapy: neuroscience for intellectual disability and dementia.

Authors:  Gabriele Sansevero; Alessandro Sale
Journal:  Oncotarget       Date:  2017-01-24

7.  Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.

Authors:  Syed Faraz Kazim; Julie Blanchard; Riccardo Bianchi; Khalid Iqbal
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

8.  Inflammation-induced miRNA-155 inhibits self-renewal of neural stem cells via suppression of CCAAT/enhancer binding protein β (C/EBPβ) expression.

Authors:  Kayoko Obora; Yuta Onodera; Toshiyuki Takehara; John Frampton; Joe Hasei; Toshifumi Ozaki; Takeshi Teramura; Kanji Fukuda
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

Review 9.  Future Perspectives in Oxidative Stress in Trisomy 13 and 18 Evaluation.

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Ahsan Hameed; Adam Jacek Krętowski; Monika Zbucka-Krętowska
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.